Effect of Surefire Infusion Device on Tumor Response to Regional Intra-arterial Therapy for Primary Liver Malignancies
Status:
Recruiting
Trial end date:
2024-07-01
Target enrollment:
Participant gender:
Summary
This research study is studying the Surefire Infusion System ("Surefire") for increasing
delivery of chemotherapeutic agents delivered trans-arterially to intermediate stage
Hepatocellular Carcinoma ("HCC") (Barcelona Clinic Liver Cancer (BCLC) class B; locally
advanced, liver restricted disease patients.
The names of the study interventions involved in this study are:
-Trans-arterial chemoembolization ("TACE") with or without the utilization of Surefire